There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report), CVS Health (CVS – Research Report) and BridgeBio Pharma (BBIO – Research Report) with bullish sentiments.
Iovance Biotherapeutics (IOVA)
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Iovance Biotherapeutics yesterday and set a price target of $30.00. The company’s shares closed last Thursday at $8.68.
According to TipRanks.com, Goldstein is a 3-star analyst with an average return of
Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.00.
See today’s best-performing stocks on TipRanks >>
CVS Health (CVS)
Mizuho Securities analyst Ann Hynes assigned a Buy rating to CVS Health on February 7 and set a price target of $86.00. The company’s shares closed last Thursday at $75.08.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of
Currently, the analyst consensus on CVS Health is a Strong Buy with an average price target of $89.43, which is a 17.9% upside from current levels. In a report issued on January 25, TD Cowen also maintained a Buy rating on the stock with a $99.00 price target.
BridgeBio Pharma (BBIO)
In a report issued on February 7, Salim Syed from Mizuho Securities maintained a Buy rating on BridgeBio Pharma, with a price target of $60.00. The company’s shares closed last Thursday at $32.96.
According to TipRanks.com, Syed is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Pharma with a $48.50 average price target, which is a 42.5% upside from current levels. In a report issued on January 24, Citi also maintained a Buy rating on the stock with a $42.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IOVA:
- Unusually active option classes on open January 26th
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics call volume above normal and directionally bullish
- Iovance clinical hold does not impact other trials, says JMP Securities
- Iovance expects to quickly address clinical hold, says Barclays
